



# Comparative Epidemiology of Vancomycin-Resistant Enterococci Colonization in an Acute-Care Hospital and Its Affiliated Intermediate- and Long-Term Care Facilities in Singapore

Damon Tan,<sup>a</sup>  Htet Lin Htun,<sup>b</sup> Jocelyn Koh,<sup>c</sup> Kala Kanagasabai,<sup>d</sup> Jia-Wei Lim,<sup>b</sup> Pei-Yun Hon,<sup>b</sup> Brenda Ang,<sup>e</sup> Angela Chow<sup>b</sup>

<sup>a</sup>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

<sup>b</sup>Department of Clinical Epidemiology, Office of Clinical Epidemiology, Analytics, and Knowledge (OCEAN), Tan Tock Seng Hospital, Singapore

<sup>c</sup>Ang Mo Kio-Thye Hua Kwan Hospital, Singapore

<sup>d</sup>Ren Ci Hospital, Singapore

<sup>e</sup>Department of Infectious Disease, Tan Tock Seng Hospital, Singapore

**ABSTRACT** Vancomycin-resistant enterococci (VRE) are an important cause of nosocomial infections in acute-care hospitals (ACHs), intermediate-care facilities (ITCFs), and long-term care facilities (LTCFs). This study contemporaneously compared the epidemiology and risk factors for VRE colonization in different care settings in a health care network. We conducted a serial cross-sectional study in a 1,700-bed ACH and its six closely affiliated ITCFs and LTCFs in June and July of 2014 to 2016. Rectal swab or stool specimens were cultured for VRE. Multivariable logistic regression was used to assess for independent risk factors associated with VRE colonization. Of 5,357 participants, 523 (9.8%) were VRE colonized. VRE prevalence was higher in ACHs (14.2%) than in ITCFs (7.6%) and LTCFs (0.8%). Common risk factors between ACHs and ITCFs included prior VRE carriage, a longer duration of antibiotic therapy, surgery in the preceding 90 days, and the presence of a skin ulcer. Independent risk factors specific to ACH-admitted patients were prior methicillin-resistant *Staphylococcus aureus* carriage, a higher number of beds per room, prior proton pump inhibitor use, and a length of stay of >14 days. For ITCFs, a length of stay of >14 days was inversely associated with VRE colonization. Similarities and differences in risk factors for VRE colonization were observed between health care settings. VRE prevention efforts should target the respective high-risk patients.

**KEYWORDS** epidemiology, vancomycin-resistant enterococci, acute-care hospital, intermediate-care facilities, long-term care facilities

Vancomycin-resistant enterococci (VRE) are Gram-positive cocci with phenotypic resistance against glycopeptides (1). VRE have the ability to avoid the damage caused by ethanol-based disinfectants (2) and can survive in health care environments for prolonged periods (3), posing significant threats to patient safety. Furthermore, VRE are capable of donating resistance plasmids to methicillin-resistant *Staphylococcus aureus* (MRSA), producing vancomycin-resistant *Staphylococcus aureus* (VRSA) (4).

VRE were first reported in 1986 in acute-care hospitals (ACHs) in the United Kingdom (5). Since then, the global prevalence of VRE has risen steadily (6). *Enterococcus* is the third most prevalent nosocomial pathogen causing bacteremia (7), with 60% of *Enterococcus faecium* isolates demonstrating vancomycin resistance (8). Since the first reported case of VRE in Singapore in 1996 (9), several outbreaks of VRE have occurred (10). The first outbreak was reported in the country's largest ACH. Subsequent out-

Received 17 July 2018 Returned for modification 13 August 2018 Accepted 7 September 2018

Accepted manuscript posted online 17 September 2018

**Citation** Tan D, Htun HL, Koh J, Kanagasabai K, Lim J-W, Hon P-Y, Ang B, Chow A. 2018. Comparative epidemiology of vancomycin-resistant enterococci colonization in an acute-care hospital and its affiliated intermediate- and long-term care facilities in Singapore. *Antimicrob Agents Chemother* 62:e01507-18. <https://doi.org/10.1128/AAC.01507-18>.

**Copyright** © 2018 American Society for Microbiology. All Rights Reserved.

Address correspondence to Angela Chow, [angela\\_chow@ttsh.com.sg](mailto:angela_chow@ttsh.com.sg).

D.T. and H.L.H. contributed equally to this article.

breaks involved multiple hospitals (11, 12), following which a rapid increase in VRE prevalence was observed in ACHs (13), raising concerns of VRE transmission to intermediate- and long-term care facilities (ILTCFs) (14).

VRE colonization is associated with increased mortality (15), particularly in leukemic, transplant, and critically ill patients, leading to early mortality (16, 17). A prolonged duration of VRE colonization after hospital discharge is associated with surgery, antibiotic use during admission, and discharge to a nursing home (18). With the frequent movement of patients between health care facilities, acute-care hospitals (ACHs) and ILTCFs form a contiguous epidemiological network (19).

Globally, the factors leading to colonization in ILTCFs are not well understood, although risk factors in ACHs have been more widely studied (20–22). A recent study in six short-stay nursing facilities in the United States which provide post-acute care to patients discharged from ACHs attempted to compare risk factors for VRE colonization on admission and at discharge from such intermediate-care facilities (ITCFs) (23). Another study in northern Italy performed point prevalence surveys in three long-term care facilities (LTCFs) to assess the prevalence and risk factors of VRE colonization (24). Thus far, the only published study that has compared the epidemiology of VRE colonization in an ACH with that in its affiliated long-term care unit was in the United States in 1997 (25). Since then, the epidemiology of VRE has changed significantly (26). To our knowledge, there have not been any recent published studies comparing the epidemiology of VRE between an ACH and its affiliated ILTCFs.

The infrastructure, clinical practice, and patient profiles in ACHs and ILTCFs differ substantially. While the general principles of infection control are applicable, interventions must be tailored to the specific context of the health care settings in order for them to be effective (14). Understanding the comparative epidemiology of VRE colonization in an interconnected health care network of an ACH, ITCFs, and LTCFs would enable the development of strategies for the prevention and control of VRE not only within institutions but also between institutions (27).

Hence, our study's objectives were to contemporaneously compare the epidemiology of VRE colonization in an ACH and its affiliated ITCFs and LTCFs in a health care network and to identify setting-specific risk factors that can guide the development of tailored infection prevention and control strategies.

## RESULTS

During the study period, 2,956, 1,244, and 1,157 patients from the ACH, ITCFs, and LTCFs, respectively, were screened for VRE. Table 1 summarizes the patients' characteristics. Participants were predominantly male ( $n = 2,876$ ; 53.7%), and the median age was 73 years (interquartile range [IQR], 62 to 81 years). Of the 5,357 participants, 523 (9.8%) were colonized with VRE, the majority of which were genotypically *vana* (93.3%). The VRE prevalence was higher in the ACH ( $n = 419$ ; 14.2%) than in the ITCFs ( $n = 95$ ; 7.6%) and LTCFs ( $n = 9$ ; 0.8%) (Table 1). In the ACH, the VRE prevalence decreased from 19.8% in 2014 to 14.0% in 2015 to 8.9% in 2016 ( $P$  value for trend [ $P_{\text{trend}}$ ] < 0.001). This was consistent with the decline in the hospital's annual VRE screening colonization and clinical infection rates over the 3 years. Conversely, the VRE prevalence in LTCFs increased marginally from 0.3% in 2014 to 1.1% in 2016 ( $P_{\text{trend}} = 0.12$ ). In ITCFs, the VRE prevalence rose from 5.1% in 2014 to 9.9% in 2015 ( $P < 0.01$ ) and then decreased to 7.4% in 2016 ( $P = 0.18$ ) (Fig. 1). There was no VRE outbreak in the institutions during the study period.

Regardless of the type of admitting health care facility, associations were observed between VRE colonization and the use of indwelling invasive devices, including peripheral lines and indwelling urinary catheters; exposures to proton pump inhibitors (PPI) and major classes of antibiotics, such as aminoglycosides, cephalosporins, fluoroquinolones, penicillin, and vancomycin; the presence of a wound or a skin ulcer; and prior carriage of MRSA (Table 2). Colonization with VRE was found to be associated with (i) prior surgery, prior VRE carriage, and a longer duration of antibiotic therapy in ACH and ITCF patients and (ii) the use of a percutaneous endoscopic gastrostomy tube and


**TABLE 1** Characteristics of patients and health care facilities<sup>a</sup>

Characteristic	Values for patients in:			
	Total (n = 5,357)	ACH (n = 2,956)	ITCFs (n = 1,244)	LTCFs (n = 1,157)
Age (yr)				
Median (IQR)	73 (62–81)	74 (62–82)	73 (63–80)	72 (61–82)
Range	21–106	21–106	25–99	27–106
No. (%) of patients >65 yr of age	3,607 (67.3)	1,989 (67.3)	865 (69.5)	753 (65.1)
No. (%) of patients by gender				
Male	2,876 (53.7)	1,626 (55.0)	638 (51.3)	612 (52.9)
Female	2,481 (46.3)	1,330 (45.0)	606 (48.7)	545 (47.1)
No. (%) of patients by ethnicity				
Chinese	4,096 (76.5)	2,341 (79.2)	1,011 (81.3)	744 (64.3)
Malay	713 (13.3)	276 (9.3)	120 (9.6)	317 (27.4)
Indian	412 (7.7)	254 (8.6)	85 (6.8)	73 (6.3)
Others	136 (2.5)	85 (2.9)	28 (2.3)	23 (2.0)
No. (%) of subsidized patients	4,995 (93.2)	2,709 (91.6)	1,130 (90.8)	1,156 (99.9)
No. (%) of patients with the following no. of beds per room:				
1	446 (8.3)	422 (14.3)	20 (1.6)	4 (0.3)
2–4	392 (7.3)	283 (9.6)	70 (5.6)	39 (3.4)
5–8	3,340 (62.4)	2,067 (69.9)	840 (67.5)	433 (37.4)
>8	1,179 (22.0)	184 (6.2)	314 (25.2)	681 (58.9)
No. (%) of patients screened for VRE in the following yr:				
2014	1,673 (31.2)	976 (33.0)	354 (28.4)	343 (29.6)
2015	1,794 (33.5)	969 (32.8)	456 (36.7)	369 (31.9)
2016	1,890 (35.3)	1,011 (34.2)	434 (34.9)	445 (38.5)
No. (%) of patients with the following source of specimen:				
Rectal swab	5,163 (96.4)	2,829 (95.7)	1,210 (97.3)	1,124 (97.2)
Stool	194 (3.6)	127 (4.3)	34 (2.7)	33 (2.8)
No. (%) of patients colonized with VRE	523 (9.8)	419 (14.2)	95 (7.6)	9 (0.8)
No. (%) of patients with VRE of the following genotype:				
<i>vanA</i>	488 (93.3)	390 (93.1)	90 (94.7)	8 (88.9)
<i>vanB</i>	31 (5.9)	28 (6.7)	2 (2.1)	1 (11.1)
<i>vanA</i> and <i>vanB</i>	4 (0.8)	1 (0.2)	3 (3.2)	0 (0.0)

<sup>a</sup>Abbreviations: ACH, acute-care hospital; ITCFs, intermediate-term care facilities; IQR, interquartile range; LTCFs, long-term care facilities; VRE, vancomycin-resistant enterococci.

prior hospital admission for acute care in ACH and LTCF patients. We observed that an age of >65 years, a Charlson's comorbidity index (CCI) of >5, and a longer length of stay were associated with VRE colonization in ACH patients, whereas males were more likely than females to be colonized with VRE in ITCFs.

**Multivariable analysis.** After adjusting for age, gender, comorbidities, year of screening, and the health care facility, prior VRE (odds ratio [OR], 5.23; 95% confidence interval [CI], 3.43 to 7.97;  $P < 0.001$ ) and MRSA (OR, 1.83; 95% CI, 1.46 to 2.29;  $P < 0.001$ ) carriage, a length of stay of >14 days (OR, 0.61; 95% CI, 0.38 to 0.96;  $P = 0.03$ ), a higher number of beds per room (2 to 4 beds/room [OR, 1.37; 95% CI, 0.86 to 2.20;  $P = 0.19$ ], 5 to 8 beds/room [OR, 1.61; 95% CI, 1.14 to 2.27;  $P < 0.01$ ], and >8 beds/room [OR, 2.06; 95% CI, 1.32 to 3.23;  $P < 0.01$ ]), exposures to PPI (OR, 1.63; 95% CI, 1.24 to 2.14;  $P < 0.01$ ), a longer duration of antibiotic therapy (1 to 3 days [OR, 2.79; 95% CI, 1.37 to 5.70;  $P < 0.01$ ], 4 to 7 days [OR, 3.59; 95% CI, 1.93 to 6.67;  $P < 0.001$ ], and >7 days [OR, 5.62; 95% CI, 3.20 to 9.87;  $P < 0.001$ ]), surgery in the past 90 days (OR, 1.44; 95% CI, 1.17 to 1.79;  $P < 0.01$ ), the presence of a skin ulcer (OR, 1.74; 95% CI, 1.40 to 2.17;  $P < 0.001$ ), and the use of an indwelling urinary catheter (OR, 1.63; 95% CI, 1.04 to 2.56;  $P = 0.03$ ) were independently associated with VRE colonization (Table 3). A significant interaction between the admitting health care facility and a length of stay of >14 days was observed (OR, 2.61; 95% CI, 1.55 to 4.39;  $P < 0.001$ ) (Table 3).



**FIG 1** Trends of vancomycin-resistant enterococci (VRE) point prevalence in the acute-care hospital (ACH), intermediate-term care facilities (ITCFs), and long-term-care facilities (LTCFs) from 2014 to 2016. *P* values were derived from the Z test.

The modifying effects of the health care facility were further assessed by stratification (Table 4). Due to the small number of VRE-colonized patients ( $n = 9$ ) among residents of LTCFs, no significant risk factors could be identified (data not presented). As such, the stratified analysis included only the ACH and ITCFs.

For ACH-admitted patients, prior VRE (OR, 6.29; 95% CI, 3.86 to 10.25,  $P < 0.001$ ) and MRSA (OR, 1.87; 95% CI, 1.44 to 2.43;  $P < 0.001$ ) carriage, a length of stay of  $>14$  days (OR, 1.71; 95% CI, 1.32 to 2.21;  $P < 0.001$ ), a higher number of beds per room (2 to 4 beds per room [OR, 1.54; 95% CI, 0.94 to 2.53;  $P = 0.09$ ], 5 to 8 beds per room [OR, 1.79; 95% CI, 1.24 to 2.57;  $P < 0.01$ ], and  $>8$  beds per room [OR, 2.12; 95% CI, 1.24 to 3.62;  $P < 0.01$ ]), exposures to PPI (OR, 1.61; 95% CI, 1.16 to 2.22;  $P < 0.01$ ), and a longer duration of antibiotic therapy (1 to 3 days [OR, 2.93; 95% CI, 1.34 to 6.41;  $P < 0.01$ ], 4 to 7 days [OR, 3.35; 95% CI, 1.67 to 6.71;  $P < 0.01$ ], and  $>7$  days [OR, 4.44; 95% CI, 2.32 to 8.51;  $P < 0.001$ ]), surgery in the past 90 days (OR, 1.45; 95% CI, 1.14 to 1.85;  $P < 0.01$ ), and the presence of a skin ulcer (OR, 1.65; 95% CI, 1.27 to 2.13;  $P < 0.001$ ) were independently associated with VRE colonization, after adjusting for potential confounders (Table 4).

For ITCFs, the significant independent factors associated with VRE colonization included prior VRE carriage (OR, 3.45; 95% CI, 1.16 to 10.28;  $P = 0.03$ ), a length of stay of  $>14$  days (OR, 0.51; 95% CI, 0.32 to 0.84;  $P < 0.01$ ),  $>7$  days of antibiotic therapy (OR, 7.80; 95% CI, 2.35 to 25.87;  $P < 0.01$ ), surgery in the past 90 days (OR, 1.62; 95% CI, 1.00 to 2.62;  $P = 0.05$ ), and the presence of a skin ulcer (OR, 1.99; 95% CI, 1.22 to 3.24;  $P < 0.01$ ). No significant associations were found for a higher number of beds per room and prior admission to ACHs (the ACH in the health care network and other ACHs) (Table 4).

## DISCUSSION

This study enabled the comparison of VRE epidemiology in an ACH and its closely affiliated ILTCFs in a health care network over 3 years. VRE colonization was more prevalent in the ACH (14.2%) than in the ILTCFs, with a significantly higher prevalence in ITCFs (7.6%) than in LTCFs (0.8%). The VRE prevalence in the ACH, ITCFs, and LTCFs was lower than that reported in similar facilities in the United States (23, 28), but the low prevalence in LTCFs was similarly observed in LTCFs in two Italian cities (24).

The contemporaneous assessment identified similarities and differences in factors associated with VRE colonization in the ACH *vis-à-vis* ITCFs. For both the ACH and ITCFs,

**TABLE 2** Univariate analysis of epidemiologic and clinical risk factors for VRE colonization in ACH, ITCFs, and LTCFs<sup>d</sup>

Characteristic	Value(s) for patients in:								
	ACH (n = 2,956)			ITCFs (n = 1,244)			LTCFs (n = 1,157)		
	VRE positive (n = 419)	VRE negative (n = 2,537)	P <sub>1</sub>	VRE positive (n = 95)	VRE negative (n = 1,149)	P <sub>2</sub>	VRE positive (n = 9)	VRE negative (n = 1,148)	P <sub>3</sub>
<b>Demographics</b>									
Median (IQR) age (yr)	75 (63–83)	73 (62–82)	0.05 <sup>b</sup>	74 (64–80)	73 (63–80)	0.83 <sup>b</sup>	75 (60–76)	72 (61–82)	0.60 <sup>b</sup>
No. (%) of patients >65 yr of age	301 (71.8)	1,688 (66.5)	0.03	68 (71.6)	797 (69.4)	0.65	6 (66.7)	747 (65.1)	1.00 <sup>c</sup>
No. (%) of male patients	247 (59.0)	1,379 (54.4)	0.08	60 (63.2)	578 (50.3)	0.02	6 (66.7)	606 (52.8)	0.51 <sup>c</sup>
<b>Comorbidities</b>									
Median (IQR) CCI	4 (2–6)	3 (1–6)	<0.001	3 (2–5)	3 (1–4)	<0.001	4 (1–5)	2 (1–4)	0.48
No. (%) of patients with CCI of >5	144 (34.4)	657 (25.9)	<0.001	15 (15.8)	131 (11.4)	0.20	2 (22.2)	146 (12.7)	0.32 <sup>c</sup>
No. (%) of patients with the following:									
Congestive cardiac failure	94 (22.4)	390 (15.4)	<0.001	16 (16.8)	80 (7.0)	<0.01	1 (11.1)	83 (7.2)	0.49 <sup>c</sup>
Chronic pulmonary disease	56 (13.4)	317 (12.5)	0.62	14 (14.7)	85 (7.4)	0.01	2 (22.2)	88 (7.7)	0.15 <sup>c</sup>
Peptic ulcer disease	41 (9.8)	178 (7.0)	0.05	6 (6.3)	50 (4.4)	0.43 <sup>c</sup>	0 (0.0)	66 (5.8)	1.00 <sup>c</sup>
Peripheral vascular disease	81 (19.3)	239 (9.4)	<0.001	81 (19.3)	239 (9.4)	<0.001	17 (16.4)	273 (11.9)	0.17
Renal disease	175 (41.8)	731 (28.8)	<0.001	35 (36.8)	221 (19.2)	<0.001	2 (22.2)	174 (15.2)	0.63 <sup>c</sup>
Hemodialysis	50 (28.6)	121 (16.6)	<0.001	13 (37.1)	56 (25.3)	0.14	0 (0.0)	14 (8.1)	1.00 <sup>c</sup>
No. (%) of patients with the following indwelling devices:									
Central venous line	72 (17.2)	248 (9.8)	<0.001	12 (12.6)	65 (5.7)	<0.01	0 (0.0)	11 (1.0)	1.00 <sup>c</sup>
Arterial line	119 (28.4)	482 (19.0)	<0.001	14 (14.7)	122 (10.6)	0.22	0 (0.0)	18 (1.6)	1.00 <sup>c</sup>
Peripheral line	413 (98.6)	2,353 (92.8)	<0.001	90 (94.7)	975 (84.9)	<0.01	9 (100.0)	439 (38.2)	<0.001 <sup>c</sup>
Peripherally inserted central catheter	45 (10.7)	96 (3.8)	<0.001	18 (18.9)	64 (5.6)	<0.001	0 (0.0)	13 (1.1)	1.00 <sup>c</sup>
Dialysis line	60 (14.3)	156 (6.2)	<0.001	13 (13.7)	59 (5.1)	<0.01	0 (0.0)	15 (1.3)	1.00 <sup>c</sup>
Tracheostomy	32 (7.6)	120 (4.7)	0.01	11 (11.6)	34 (3.0)	<0.001	1 (11.1)	111 (10.0)	0.60 <sup>c</sup>
Endotracheal tube	72 (17.2)	369 (14.5)	0.16	17 (17.9)	152 (13.2)	0.20	0 (0.0)	21 (1.8)	1.00 <sup>c</sup>
Nasogastric tube	179 (42.7)	724 (28.5)	<0.001	33 (34.7)	248 (21.6)	<0.01	8 (88.9)	428 (37.3)	<0.01 <sup>c</sup>
Chest tube	8 (1.9)	63 (2.5)	0.48	2 (2.1)	11 (1.0)	0.26 <sup>c</sup>	0 (0.0)	3 (0.3)	1.00 <sup>c</sup>
PEG tube	86 (20.5)	271 (10.7)	<0.001	10 (10.5)	72 (6.3)	0.11	3 (33.3)	71 (6.2)	0.02 <sup>c</sup>
Suprapubic catheter	1 (0.2)	15 (0.6)	0.72 <sup>c</sup>	1 (1.1)	4 (0.4)	0.33 <sup>c</sup>	0 (0.0)	17 (1.5)	1.00 <sup>c</sup>
Indwelling urinary catheter	199 (47.5)	809 (31.9)	<0.001	50 (52.6)	397 (34.6)	<0.001	4 (44.4)	179 (15.6)	0.04 <sup>c</sup>
Colostomy	14 (3.3)	30 (1.2)	<0.01	2 (2.1)	11 (1.0)	0.26 <sup>c</sup>	0 (0.0)	10 (0.9)	1.00 <sup>c</sup>
<b>Details of current and prior hospital admissions</b>									
Median (IQR) length of stay (days)	15 (9–30)	9 (6–16)	<0.001 <sup>b</sup>	20 (10–36)	22 (11–37)	0.19 <sup>b</sup>	691 (139–2,407)	503 (223–1,665)	0.69 <sup>b</sup>
No. (%) of subsidized patients	404 (96.4)	2,305 (90.9)	<0.001	86 (90.5)	1,044 (90.9)	0.91	9 (100.0)	1,147 (99.9)	1.00 <sup>c</sup>
No. (%) of patients with prior ICU admission	28 (6.7)	88 (3.5)	<0.01	22 (23.2)	143 (12.5)	<0.01	0 (0.0)	28 (2.4)	1.00 <sup>c</sup>
No. (%) of patients with prior admission to ACH									
None	157 (37.5)	1,440 (56.8)	<0.001	2 (2.1)	85 (7.4)	0.08	1 (11.1)	695 (60.5)	<0.01 <sup>c</sup>
Study ACH	262 (62.5)	1,097 (43.2)	<0.001	46 (48.4)	588 (51.2)	0.08	6 (66.7)	227 (19.8)	
Other ACHs				47 (49.5)	476 (41.4)		2 (22.2)	226 (19.7)	
No. of prior admissions to ACH									
Median (IQR)	2 (1–4)	1 (1–3)	<0.001 <sup>b</sup>	2 (1–3)	1 (1–2)	<0.001 <sup>b</sup>	3 (2–4)	1 (1–2)	<0.01 <sup>b</sup>
Range	1–20	1–25		1–9	1–19		1–8	1–10	
No. (%) patients using the following medications:									
Antacid	11 (2.6)	67 (2.6)	0.99	4 (4.2)	55 (4.8)	1.00 <sup>c</sup>	0 (0.0)	17 (1.5)	1.00 <sup>c</sup>
Proton pump inhibitors	364 (86.9)	1,802 (71.0)	<0.001	77 (81.1)	723 (62.9)	<0.001	7 (77.8)	488 (42.5)	0.04 <sup>c</sup>
H2 antagonists	74 (17.7)	354 (14.0)	0.05	6 (6.3)	164 (14.3)	0.03	4 (44.4)	189 (16.5)	0.05 <sup>c</sup>
Corticosteroids	94 (22.4)	520 (20.5)	0.37	23 (24.2)	166 (14.5)	0.01	3 (33.3)	118 (10.3)	0.06 <sup>c</sup>
Aminoglycosides	187 (44.6)	784 (30.9)	<0.001	24 (25.3)	139 (12.1)	<0.001	5 (55.6)	114 (9.9)	<0.01 <sup>c</sup>
Carbapenems	140 (33.4)	345 (13.6)	<0.001	28 (29.5)	107 (9.3)	<0.001	1 (11.1)	49 (4.3)	0.33 <sup>c</sup>
Cephalosporins	199 (47.5)	738 (29.1)	<0.001	49 (51.6)	344 (29.9)	<0.001	4 (44.4)	133 (11.6)	0.02 <sup>c</sup>
Fluoroquinolones	139 (33.2)	471 (18.6)	<0.001	43 (45.3)	276 (24.0)	<0.001	7 (77.8)	237 (20.6)	<0.001 <sup>c</sup>
Penicillin	367 (87.6)	1,738 (68.5)	<0.001	80 (84.2)	645 (56.1)	<0.001	9 (100.0)	590 (51.4)	<0.01 <sup>c</sup>
Vancomycin	267 (63.7)	771 (30.4)	<0.001	40 (42.1)	170 (14.8)	<0.001	6 (66.7)	96 (8.4)	<0.001 <sup>c</sup>
No. (%) patients with the following no. of days of antibiotic therapy <sup>d</sup> :									
None	11 (2.6)	468 (18.4)	<0.001	3 (3.2)	315 (27.4)	<0.001 <sup>c</sup>	0 (0.0)	437 (38.1)	0.06 <sup>c</sup>
1–3	18 (4.3)	238 (9.4)		1 (1.0)	84 (7.3)		0 (0.0)	9 (0.8)	
4–7	42 (10.0)	428 (16.9)		5 (5.3)	125 (10.9)		0 (0.0)	89 (7.7)	
>7	348 (83.1)	1,403 (55.3)		84 (88.4)	595 (51.8)		9 (100.0)	606 (52.8)	
Unknown				2 (2.1)	30 (2.6)		0 (0.0)	7 (0.6)	
<b>Surgery, wounds, and ulcers</b>									
No. (%) patients with surgery in the past:									
30 days	171 (40.8)	854 (33.7)	<0.01	21 (22.1)	262 (22.8)	0.88	1 (11.1)	19 (1.7)	0.15 <sup>c</sup>
90 days	218 (52.0)	1,036 (40.8)	<0.001	60 (63.2)	518 (45.1)	<0.01	2 (22.2)	50 (4.4)	0.06 <sup>c</sup>
180 days	240 (57.3)	1,140 (44.9)	<0.001	66 (69.5)	600 (52.2)	<0.01	2 (22.2)	91 (7.9)	0.16 <sup>c</sup>
365 days	252 (60.1)	1,262 (49.7)	<0.001	68 (71.6)	635 (55.3)	<0.01	2 (22.2)	179 (15.6)	0.64 <sup>c</sup>

(Continued on next page)

TABLE 2 (Continued)

Characteristic	Value(s) for patients in:								
	ACH (n = 2,956)			ITCFs (n = 1,244)			LTCFs (n = 1,157)		
	VRE positive (n = 419)	VRE negative (n = 2,537)	$P_1$	VRE positive (n = 95)	VRE negative (n = 1,149)	$P_2$	VRE positive (n = 9)	VRE negative (n = 1,148)	$P_3$
No. (%) patients with a wound	259 (61.8)	903 (35.6)	<0.001	65 (68.4)	637 (55.4)	0.01	7 (77.8)	413 (36.0)	0.01 <sup>c</sup>
No. (%) patients with a skin ulcer	169 (40.3)	479 (18.9)	<0.001	37 (39.0)	229 (19.9)	<0.001	5 (55.6)	196 (17.1)	0.01 <sup>c</sup>
Prior carriage of antimicrobial-resistant organism									
VRE	55 (13.1)	39 (1.5)	<0.001	7 (7.4)	13 (1.1)	<0.001 <sup>c</sup>	1 (11.1)	29 (2.5)	0.21 <sup>c</sup>
CRE	6 (1.4)	30 (1.2)	0.67	2 (2.1)	5 (0.4)	0.09 <sup>c</sup>	0 (0.0)	2 (0.2)	1.00 <sup>c</sup>
MRSA	180 (43.0)	450 (17.7)	<0.001	29 (30.5)	191 (16.6)	<0.01	5 (55.6)	131 (11.4)	<0.01 <sup>c</sup>

<sup>a</sup>Days of antibiotic therapy included the use of any antibiotics comprising an aminoglycoside, a carbapenem, a cephalosporin, a fluoroquinolone, penicillin, or vancomycin in the preceding 12 months.

<sup>b</sup>Wilcoxon rank-sum test.

<sup>c</sup>Fisher's exact test.

<sup>d</sup>Abbreviations: ACH, acute-care hospital; CCI, Charlson's comorbidity index; CRE, carbapenem-resistant enterococci; ITCFs, intermediate-term care facilities; IQR, interquartile range; LTCFs, long-term care facilities; MRSA, methicillin-resistant *Staphylococcus aureus*; PEG, percutaneous endoscopic gastrostomy; VRE, vancomycin-resistant enterococci.  $P_1$ , statistical test between VRE-positive and -negative patients in acute-care hospital;  $P_2$ , statistical test between VRE-positive and -negative patients in intermediate-term care facilities;  $P_3$ , statistical test between VRE-positive and -negative patients in long-term care facilities.

prior VRE carriage, the duration of antibiotic therapy, surgery in the past 90 days, and the presence of a skin ulcer were common risk factors. Factors such as the number of beds per room, prior MRSA carriage, and length of stay had different effects in the ACH than in ITCFs. While an increase in the number of beds per room, prior PPI use, prior MRSA carriage, and a prolonged length of stay of >14 days at the ACH were associated with an increased risk for VRE colonization at the ACH, they were not found to be risk factors in ITCFs. Notably, a length of stay of >14 days in ITCFs was inversely associated with VRE colonization.

We found that PPI use was a significant risk factor for VRE colonization, a finding consistent with that of previous studies (29, 30). An animal study showed that suppression of gastric acid by PPI acted in combination with other factors that disrupt the colonic microflora to encourage VRE colonization (30). Other studies have shown that H2 antagonists, which also increase gastric pH, are not associated with VRE colonization (31), similar to our study's finding.

We further observed that the use of antibiotics of all classes predisposed both ACH- and ITCF-admitted patients to VRE colonization. This is consistent with previous reports suggesting that antibiotic pressure selected for vancomycin resistance in enterococci (32–34). This also highlights the importance of good antimicrobial stewardship not only in ACHs but also in ITCFs for the prevention of VRE.

The presence of skin ulcers doubled the risk of VRE colonization in patients from both the ACH and ITCFs. This is consistent with the findings of prior studies in ACHs (35) and ITCFs (36) showing that ulcers are independently associated with a higher risk of VRE colonization. A prior study suggested further surveillance of VRE colonization in patients with decubitus ulcers due to the potential spread of vancomycin resistance genes to staphylococci (35).

Our study illustrated that the effect of the duration of hospitalization was modified by the type of health care facility at which the patient was hospitalized. A length of stay of >14 days was positively associated with colonization in the ACH but inversely associated with colonization in ITCFs. Benenson et al also reported that a shorter duration of stay was associated with a higher risk of VRE colonization in ITCFs (37). Mody et al. have further observed that a prolonged hospitalization of >14 days at an ACH prior to admission to the ITCF (adjusted OR, 2.15; 95% CI, 1.11 to 4.16) was an independent predictor of colonization with multidrug-resistant organisms (MRSA, VRE, and resistant Gram-negative bacilli), even after adjusting for the duration of stay in the ITCF (23). These findings suggest that patients might have been colonized in ACHs before transfer to ITCFs. A recent study conducted in the United Kingdom used whole-genome sequencing to demonstrate that LTCF residents acquired VRE from the ACH in the health care network and could transmit existing strains to ACH patients and



**TABLE 3** Multivariable logistic regression analysis of epidemiologic and clinical risk factors for VRE colonization<sup>b</sup>

Characteristic	Model 1		Model 2		Model 3		Model 4 (final model)	
	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
<b>Demographics</b>								
Age (yr)	1.00 (0.99–1.01)	0.55	1.00 (1.00–1.01)	0.32	1.00 (1.00–1.01)	0.27	1.00 (1.00–1.01)	0.24
Male	1.16 (0.94–1.42)	0.16	1.15 (0.94–1.41)	0.18	1.16 (0.94–1.42)	0.16	1.16 (0.94–1.42)	0.17
<b>Yr of screening</b>								
2014	Reference		Reference		Reference		Reference	
2015	0.79 (0.63–1.00)	0.05	0.78 (0.62–0.98)	0.03	0.77 (0.61–0.98)	0.03	0.78 (0.62–0.98)	0.04
2016	0.47 (0.37–0.61)	<0.001	0.45 (0.35–0.58)	<0.001	0.45 (0.35–0.57)	<0.001	0.45 (0.35–0.57)	<0.001
<b>Comorbidities and prior carriage of antimicrobial-resistant organism</b>								
CCI > 5	0.98 (0.78–1.22)	0.83	0.91 (0.73–1.15)	0.44	0.89 (0.71–1.13)	0.35	0.89 (0.70–1.12)	0.33
Prior carriage of VRE	5.86 (3.91–8.79)	<0.001	5.69 (3.77–8.59)	<0.001	5.32 (3.50–8.09)	<0.001	5.23 (3.43–7.97)	<0.001
Prior carriage of MRSA	2.00 (1.61–2.48)	<0.001	1.86 (1.49–2.33)	<0.001	1.85 (1.47–2.31)	<0.001	1.83 (1.46–2.29)	<0.001
<b>Details of current and prior hospital admissions</b>								
<b>Admitted to health care facility</b>								
ACH	Reference		Reference		Reference		Reference	
ITCFs	0.50 (0.38–0.65)	<0.001	0.48 (0.37–0.63)	<0.001	0.49 (0.37–0.64)	<0.001	0.77 (0.48–1.24)	0.28
LTCFs	0.04 (0.02–0.09)	<0.001	0.05 (0.03–0.11)	<0.001	0.06 (0.03–0.13)	<0.001	0.05 (0.02–0.13)	<0.001
Length of stay of >14 days	1.42 (1.14–1.76)	<0.01	1.32 (1.06–1.65)	0.01	1.28 (1.02–1.60)	0.03	0.61 (0.38–0.96)	0.03
Prior admission to study ACH	1.08 (0.87–1.35)	0.48	1.05 (0.84–1.31)	0.66	1.00 (0.80–1.25)	0.99	1.01 (0.80–1.26)	0.96
<b>No. of beds per room</b>								
1	Reference		Reference		Reference		Reference	
2–4	1.43 (0.90–2.28)	0.13	1.36 (0.85–2.18)	0.20	1.36 (0.85–2.18)	0.20	1.37 (0.86–2.20)	0.19
5–8	1.57 (1.12–2.21)	<0.01	1.61 (1.14–2.26)	<0.01	1.61 (1.14–2.27)	<0.01	1.61 (1.14–2.27)	<0.01
>8	1.99 (1.28–3.09)	<0.01	2.13 (1.37–3.33)	<0.01	2.14 (1.37–3.35)	<0.01	2.06 (1.32–3.23)	<0.01
Proton pump inhibitor use	1.79 (1.37–2.34)	<0.001	1.70 (1.29–2.22)	<0.001	1.63 (1.24–2.15)	<0.001	1.63 (1.24–2.14)	<0.01
<b>No. of days of antibiotic therapy<sup>a</sup></b>								
0	Reference		Reference		Reference		Reference	
1–3	3.24 (1.59–6.58)	<0.01	3.04 (1.49–6.19)	<0.01	2.77 (1.36–5.65)	<0.01	2.79 (1.37–5.70)	<0.01
4–7	4.13 (2.24–7.62)	<0.001	4.00 (2.17–7.39)	<0.001	3.57 (1.92–6.63)	<0.001	3.59 (1.93–6.67)	<0.001
>7	7.54 (4.34–13.09)	<0.001	6.54 (3.76–11.38)	<0.001	5.69 (3.24–9.98)	<0.001	5.62 (3.20–9.87)	<0.001
Unknown	4.10 (0.87–19.36)	0.08	3.52 (0.74–16.84)	0.12	3.10 (0.65–14.85)	0.16	2.97 (0.62–14.15)	0.17
<b>Surgery and ulcer</b>								
Surgery in the past 90 days			1.59 (1.29–1.96)	<0.001	1.51 (1.23–1.87)	<0.001	1.44 (1.17–1.79)	<0.01
Presence of a skin ulcer			1.70 (1.37–2.11)	<0.001	1.68 (1.35–2.09)	<0.001	1.74 (1.40–2.17)	<0.001
<b>Indwelling devices</b>								
Peripheral line					1.79 (0.94–3.43)	0.08	1.69 (0.88–3.25)	0.12
Dialysis line					1.29 (0.92–1.80)	0.14	1.29 (0.92–1.81)	0.14
PEG tube					0.93 (0.70–1.24)	0.64	0.91 (0.68–1.21)	0.52
Indwelling urinary catheter					1.24 (1.01–1.53)	0.04	1.63 (1.04–2.56)	0.03
<b>Interaction between ACH and:</b>								
Length of stay of >14 days							2.61 (1.55–4.39)	<0.001
Presence of an indwelling urinary catheter							0.69 (0.42–1.14)	0.15
<b>Model assessment</b>								
Log likelihood	–1,376.9879		–1,356.6193		–1,351.6096		–1,344.6439	
Likelihood-ratio test P value			<0.001		0.04		<0.01	
Area under ROC	0.8163		0.8229		0.8248		0.8278	

<sup>a</sup>Days of antibiotic therapy included the use of any antibiotics comprising an aminoglycoside, a carbapenem, a cephalosporin, a fluoroquinolone, penicillin, or vancomycin in the preceding 12 months.

<sup>b</sup>Data are for 5,357 patients. Abbreviations: ACH, acute-care hospital; CCI, Charlson's comorbidity index; CI, confidence interval; ITCFs, intermediate-term care facilities; LTCFs, long-term care facilities; MRSA, methicillin-resistant *Staphylococcus aureus*; OR, odds ratio; ROC, receiver operating curve; PEG, percutaneous endoscopic gastrostomy; VRE, vancomycin-resistant enterococci.

shed VRE into the environment (38). However, no evidence of VRE transmission between LTCF residents could be found. Further studies are needed to understand the transmission dynamics between ITCFs and the ACH in a health care network.

The number of beds per room was a significant risk factor for VRE colonization in the ACH. This finding was similar to that of previous studies (20, 39). This could be due to more frequent contact precaution lapses when faced with higher patient-to-staff ratios (40). However, this was not observed in ITCFs, where the care model differed from that

**TABLE 4** Multivariable logistic regression analysis of epidemiologic and clinical risk factors for VRE colonization in the ACH and ITCFs<sup>b</sup>

Characteristic	ACH (n = 2,956)		ITCFs (n = 1,244)	
	OR (95% CI)	P	OR (95% CI)	P
<b>Demographics</b>				
Age (yr)	1.01 (1.00–1.01)	0.19	1.00 (0.98–1.02)	0.82
Male	1.10 (0.87–1.39)	0.44	1.53 (0.96–2.46)	0.08
Yr of screening				
2014	Reference		Reference	
2015	0.64 (0.49–0.83)	<0.01	1.73 (0.94–3.19)	0.08
2016	0.35 (0.26–0.47)	<0.001	1.27 (0.66–2.43)	0.47
<b>Comorbidities and prior carriage of antimicrobial-resistant organism</b>				
CCI > 5	0.89 (0.69–1.16)	0.39	0.82 (0.42–1.59)	0.56
Prior carriage of VRE	6.29 (3.86–10.25)	<0.001	3.45 (1.16–10.28)	0.03
Prior carriage of MRSA	1.87 (1.44–2.43)	<0.001	1.47 (0.88–2.45)	0.14
<b>Details of current and prior hospital admissions</b>				
Length of stay >14 days	1.71 (1.32–2.21)	<0.001	0.51 (0.32–0.84)	<0.01
Prior admission to ACH				
None	Reference		Reference	
Study ACH	1.15 (0.89–1.51)	0.29	1.73 (0.37–8.02)	0.49
Other ACHs	–		2.52 (0.54–11.78)	0.24
No. of beds per room				
1	Reference		Reference	
2–4	1.54 (0.94–2.53)	0.09	0.27 (0.04–1.67)	0.16
5–8	1.79 (1.24–2.57)	<0.01	0.29 (0.07–1.14)	0.08
>8	2.12 (1.24–3.62)	<0.01	0.42 (0.10–1.73)	0.23
<b>Medication use</b>				
Proton pump inhibitors	1.61 (1.16–2.22)	<0.01	1.73 (0.98–3.08)	0.06
<b>No. of days of antibiotic therapy<sup>a</sup></b>				
0	Reference		Reference	
1–3	2.93 (1.34–6.41)	<0.01	0.81 (0.08–8.10)	0.86
4–7	3.35 (1.67–6.71)	<0.01	3.45 (0.79–15.04)	0.10
>7	4.44 (2.32–8.51)	<0.001	7.80 (2.35–25.87)	<0.01
Unknown			3.61 (0.55–23.57)	0.18
<b>Surgery and ulcer</b>				
Surgery in the past 90 days	1.45 (1.14–1.85)	<0.01	1.62 (1.00–2.62)	0.05
Presence of a skin ulcer	1.65 (1.27–2.13)	<0.001	1.99 (1.22–3.24)	<0.01
<b>Indwelling devices</b>				
Peripheral line	1.43 (0.60–3.38)	0.42	1.26 (0.45–3.49)	0.66
Dialysis line	1.24 (0.84–1.83)	0.27	1.36 (0.65–2.87)	0.41
PEG tube	0.86 (0.62–1.18)	0.35	1.28 (0.58–2.82)	0.54
Indwelling urinary catheter	1.15 (0.91–1.47)	0.25	1.54 (0.94–2.51)	0.08

<sup>a</sup>Days of antibiotic therapy included the use of any antibiotics comprising an aminoglycoside, a carbapenem, a cephalosporin, a fluoroquinolone, penicillin, or vancomycin in the preceding 12 months.

<sup>b</sup>Abbreviations: ACH, acute-care hospital; CCI, Charlson's comorbidity index; CI, confidence interval; ITCFs, intermediate-term care facilities; MRSA, methicillin-resistant *Staphylococcus aureus*; OR, odds ratio; PEG, percutaneous endoscopic gastrostomy; VRE, vancomycin-resistant enterococci.

in the ACH. Whether patients were hospitalized in single- or multibed rooms in ITCFs, they would be exposed to the common gym facilities during their physical and occupational therapies for rehabilitation.

The use of indwelling urinary catheters increased the risk of VRE colonization in ITCFs with marginal statistical significance (OR, 1.54; 95% CI, 0.94 to 2.51;  $P = 0.08$ ) but had no influence on VRE colonization in the ACH (OR, 1.15; 95% CI, 0.91 to 1.47;  $P = 0.25$ ). This could be due to the longer duration of catheter use in ITCF-admitted patients, whose conditions might require long-term catheter use. McKinnell et al. have also reported an increased risk of VRE colonization in long-stay nursing home residents who had a urinary catheter (adjusted OR, 2.7; 95% CI, 1.5 to 5.1) (28). Indwelling urinary catheters are well-known sources of colonization and infection (41), and VRE are a common cause of urinary tract infections (26, 42). Another reason could be the



know-do gap between the knowledge of best practices and the actual implementation of the evidence-based catheterization techniques in ILTCFs, a well-studied discrepancy (43, 44). Suboptimal practices predispose patients to VRE colonization (45), highlighting the importance of staff education and training on catheter management to reduce colonization risk (46).

Prior VRE carriers were 6 and 3.5 times as likely as noncarriers to be currently colonized with VRE in the ACH and ITCFs, respectively. This observation supports the strategy of preemptive isolation or cohorting with contact precautions for prior VRE carriers on admission to ACHs and ITCFs.

There was no significant relationship between comorbidities and the risk of colonization after accounting for extrinsic factors. Amenable extrinsic factors, such as exposure to antibiotics and a prolonged stay of >14 days at the ACH, were significantly associated with VRE colonization. This is corroborated by several studies examining VRE colonization in dialysis centers, where invasive devices and prolonged exposure to health care settings rather than the patients' comorbidities were suggested to be risk factors (47, 48).

The strength of this study is that it included a large sample of patients and a high participation rate (87%). Hence, selection bias, if any, was likely minimal. VRE screening samples and tests were collected and performed in a standardized manner, with the identification of bacterial colonies being confirmed with matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry, minimizing any potential measurement error and outcome misclassification. A limitation of the study was the unavailability of data on previous hospitalization in ACHs other than the study's ACH for the ACH-admitted population. However, any information bias was likely nondifferential and minimal, as the majority of patients from the study's ACH tended to be readmitted to the same ACH. Another limitation was that health care system-specific risk factors in the Singapore population, particularly under the provision of subsidized care, may not be generalizable to other health care systems.

In conclusion, we identified similarities and differences in risk factors for VRE colonization in an ACH and its affiliated ITCFs. Prior VRE carriage, exposure to antibiotics, and the presence of a skin ulcer were risk factors common to the facilities. While the increasing number of beds per room increased the colonization risk in the ACH, it was not observed in ITCFs. A length of stay of >14 days was positively associated with VRE colonization in the ACH but inversely associated with colonization in ITCFs. Infection prevention and control strategies, including preemptive contact precautions and targeted screening, could be implemented for the respective high-risk patient groups at ACHs and ITCFs.

## MATERIALS AND METHODS

**Study setting and design.** Over three 6-week periods from 2 June to July 9 2014, 22 June to 31 July 2015, and 30 June to 29 July 2016, serial cross-sectional studies were conducted in a 1,700-bed adult tertiary-care ACH in Singapore and its three most closely affiliated ITCFs, a 100-bed rehabilitation hospital, a 116-bed community hospital, and a 235-bed community hospital which expanded to 360 beds in 2015, as well as its three affiliated LTCFs, a 234-bed nursing home, a 164-bed chronic sick unit, and a 236-bed nursing home newly opened in 2015. In the ITCFs and LTCFs, no VRE screening protocol was in place throughout the study period. In the ACH, targeted on-admission VRE screening had been carried out since January 2014 for patients who had either chronic renal disease or a prior hospitalization in the preceding 12 months. Patients identified to be colonized with VRE were placed in VRE cohort wards, with enhanced contact precautions being undertaken.

We randomly selected 2,956 inpatients with a >48-h stay in the ACH during the study period to participate in the study. A random sample of 65 to 66 eligible inpatients per day, proportional to the bed census of the ward, covering all wards in the ACH was selected systematically thrice over 15 days. All residents of the ITCFs and LTCFs were included.

**Sample collection and testing.** A rectal swab sample was taken from each study participant in a standardized manner, with a saline-moistened sterile swab stick being inserted 2 inches into the rectum, twirled twice, and removed. A stool sample was taken from participants who declined rectal swab samples collection. The samples were inoculated onto ChromID VRE-selective chromogenic agar and incubated aerobically at 35 to 37°C for 48 h. Positive cultures were referred to matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry and Vitek antimicrobial suscepti-

bility testing (AST) for identification. Isolates were genotyped via PCR, using previously identified methods (49).

**Epidemiologic and clinical data.** The patients' epidemiologic and clinical data collected included sociodemographics (age, gender, and ethnicity); comorbidity (diabetes mellitus, cardiovascular disease, liver disease, renal disease, neoplasm, central nervous system disease, and chronic pulmonary disease); cognitive function; prior VRE colonization in the 12 months preceding VRE screening; prior hospitalization at the acute-care hospital in the health care network or other acute-care hospitals in the preceding 12 months; a history of surgical procedures in the preceding 12 months; the number of beds per room during the current hospital stay, which was categorized into 1, 2 to 4, 5 to 8, and >8 beds per room; the presence of a wound and/or a skin ulcer and percutaneous invasive devices in the preceding 12 months; the length of stay at the institution at the time of screening; and prior antibiotic, proton pump inhibitor (PPI), H2 antagonist, and corticosteroid exposures by any route of administration with  $\geq 1$  day of therapy (DOT) (50) in the preceding 12 months. Prior antibiotic exposure was further categorized into 0, 1 to 3, 4 to 7, and >7 DOT. Charlson's comorbidity index (CCI) (51) was computed from the presence of comorbidities and categorized into  $\leq 5$  (good) and  $> 5$  (poor premorbid status).

Data were obtained electronically from the admission and discharge databases of all institutions and electronically from medical and pharmacy records at the ACH and ILTCFs. In the ILTCFs, where electronic records were unavailable, clinical data were manually extracted from paper-based inpatient medical records by trained research assistants.

**Data analysis.** We used frequencies and percentages for categorical variables and medians and interquartile ranges (IQR) for continuous variables for descriptive analyses. The differences in characteristics between VRE-colonized and noncolonized patients were compared using the chi-square test or Fisher's exact test where appropriate. Differences in age and the duration of stay were compared using the Wilcoxon rank-sum test, as the data did not follow a normal distribution. We explored the relationships between the various patients' characteristics and colonization with VRE using multivariable logistic regression models, adjusting for potential confounders. Four nested multivariable logistic regression models were constructed, with VRE colonization being the outcome variable and the following variables being predictors: in model 1, demographics and comorbidities; current and prior hospital admission details, including length of stay and the number of beds per room; and antibiotic and PPI exposures; in model 2, addition of skin ulcers and surgery in the preceding 90 days; in model 3, addition of indwelling invasive devices; and in model 4, final addition of interaction terms between ACH and length of stay/indwelling catheter use. The models were compared against each other using the likelihood-ratio test and receiver operating curve (ROC) values, and the best-fit model was chosen as the final model. The odds ratio (OR) with the 95% confidence interval (CI) from regression analyses is presented, along with *P* values. All reported *P* values were two-tailed with an  $\alpha$  level of 0.05. All statistical analyses were performed using Stata (version 13.1) software (StataCorp LP, College Station, TX).

**Ethical approval.** Ethical approval for the study was obtained from the Domain Specific Research Board, National Healthcare Group (DSRB-2014/01139). Informed consent was provided by all cognitively intact participants or the legally authorized representatives (LARs) of cognitively impaired participants. A waiver of informed consent was granted for cognitively impaired participants from the ILTCFs who had no LARs.

## ACKNOWLEDGMENTS

We thank the patients who participated in this study and the staff who facilitated the study conduct and data collection.

None of us has a commercial or other association that might pose a conflict of interest.

This study was funded by the Ministry of Health Singapore's Communicable Diseases - Public Health Research Grant (CDPHRG/0008/2014).

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

## REFERENCES

- Fisher K, Phillips C. 2009. The ecology, epidemiology and virulence of *Enterococcus*. *Microbiology* 155:1749–1757. <https://doi.org/10.1099/mic.0.026385-0>.
- Sakagami Y, Kajimura K. 2002. Bactericidal activities of disinfectants against vancomycin-resistant enterococci. *J Hosp Infect* 50:140–144. <https://doi.org/10.1053/jhin.2001.1150>.
- Neely AN, Maley MP. 2000. Survival of enterococci and staphylococci on hospital fabrics and plastic. *J Clin Microbiol* 38:724–726.
- Hayakawa K, Marchaim D, Bathina P, Martin ET, Pogue JM, Sunkara B, Kamatam S, Ho K, Willis LB, Ajamoghli M, Patel D, Khan A, Lee KP, Suhrawardy U, Jagadeesh KK, Reddy SML, Levine M, Ahmed F, Omotola AM, Mustapha M, Moshos JA, Rybak MJ, Kaye KS. 2013. Independent risk factors for the co-colonization of vancomycin-resistant *Enterococcus faecalis* and methicillin-resistant *Staphylococcus aureus* in the region most endemic for vancomycin-resistant *Staphylococcus aureus* isolation. *Eur J Clin Microbiol Infect Dis* 32:815–820. <https://doi.org/10.1007/s10096-013-1814-z>.
- O'Driscoll T, Crank CW. 2015. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. *Infect Drug Resist* 8:217–230. <https://doi.org/10.2147/IDR.S54125>.
- Martone WJ. 1998. Spread of vancomycin-resistant enterococci: why did it happen in the United States? *Infect Control Hosp Epidemiol* 19:539–545. <https://doi.org/10.2307/30141777>.
- Miller WR, Murray BE, Rice LB, Arias CA. 2016. Vancomycin-resistant enterococci: therapeutic challenges in the 21st century. *Infect Dis Clin North Am* 30:415–439. <https://doi.org/10.1016/j.idc.2016.02.006>.
- Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. *Clin Infect Dis* 39:309–317. <https://doi.org/10.1086/421946>.

9. Ang SW, Seah CS, Lee ST. 1996. Vancomycin-resistant *Enterococcus* in the Singapore National Burns Centre: a case report. *Ann Acad Med Singapore* 25:270–272.
10. Chlebicki MP, Kurup A. 2008. Vancomycin-resistant enterococcus: a review from a Singapore perspective. *Ann Acad Med Singapore* 37:861–869.
11. Koh T, Hsu L-Y, Chiu L-L, Lin R. 2006. Emergence of epidemic clones of vancomycin-resistant *Enterococcus faecium* in Singapore. *J Hosp Infect* 63:234–236. <https://doi.org/10.1016/j.jhin.2006.01.028>.
12. Cai Y, Chan JP, Fisher DA, Hsu LY, Koh TH, Krishnan P, Kwa AL, Tan TY, Tee NW. 2012. Vancomycin-resistant enterococci in Singaporean hospitals: 5-year results of a multi-centre surveillance programme. *Ann Acad Med Singapore* 41:77–81.
13. Fisher D, Pang L, Salmon S, Lin RT, Teo C, Tambyah P, Jureen R, Cook AR, Otter JA. 2016. A successful vancomycin-resistant enterococci reduction bundle at a Singapore hospital. *Infect Control Hosp Epidemiol* 37:107–109. <https://doi.org/10.1017/ice.2015.251>.
14. Ministry of Health Singapore. 2013. Guidelines for control and prevention of multi-drug resistant organisms (MDROs) in healthcare facilities, p 1–78. Ministry of Health, Singapore. [https://www.moh.gov.sg/content/moh\\_web/home/Publications/guidelines/infection\\_control\\_guidelines/MDRO\\_Guidelines.html](https://www.moh.gov.sg/content/moh_web/home/Publications/guidelines/infection_control_guidelines/MDRO_Guidelines.html).
15. Miu D, Ling S, Tse C. 2016. Epidemiology of vancomycin-resistant enterococci in postacute care facility and predictors of clearance: a 5-year retrospective cohort study. *J Clin Gerontol Geriatr* 7:153–157. <https://doi.org/10.1016/j.jcgg.2015.11.002>.
16. Leis JF, Newton A, Post MT, Hayes-Lattin BM, Maziarz RT, Taplitz RA. 2006. Vancomycin-resistant enterococcus (VRE) colonization is associated with a high rate of bacteremia and early mortality in transplant/leukemia patients. *Blood* 108:5315.
17. Ziakas PD, Thapa R, Rice LB, Mylonakis E. 2013. Trends and significance of VRE colonization in the ICU: a meta-analysis of published studies. *PLoS One* 8:e75658. <https://doi.org/10.1371/journal.pone.0075658>.
18. Sohn KM, Peck KR, Joo E-J, Ha YE, Kang C-I, Chung DR, Lee NY, Song J-H. 2013. Duration of colonization and risk factors for prolonged carriage of vancomycin-resistant enterococci after discharge from the hospital. *Int J Infect Dis* 17:e240–e246. <https://doi.org/10.1016/j.ijid.2012.09.019>.
19. Brodrick HJ, Raven KE, Kallonen T, Jamrozny D, Blane B, Brown NM, Martin V, Török ME, Parkhill J, Peacock SJ. 2017. Longitudinal genomic surveillance of multidrug-resistant *Escherichia coli* carriage in a long-term care facility in the United Kingdom. *Genome Med* 9:70. <https://doi.org/10.1186/s13073-017-0457-6>.
20. Yang K, Fong Y, Lee H, Kurup A, Koh T, Koh D, Lim M. 2007. Predictors of vancomycin-resistant enterococcus (VRE) carriage in the first major VRE outbreak in Singapore. *Ann Acad Med Singapore* 36:379–383.
21. Byers KE, Anglim AM, Anneski CJ, Germanson TP, Gold HS, Durbin LJ, Simonton BM, Farr BM. 2001. A hospital epidemic of vancomycin-resistant *Enterococcus* risk factors and control. *Infect Control Hosp Epidemiol* 22:140–147. <https://doi.org/10.1086/501880>.
22. Padiglione AA, Wolfe R, Grabsch EA, Olden D, Pearson S, Franklin C, Spelman D, Mayall B, Johnson PD, Grayson ML. 2003. Risk factors for new detection of vancomycin-resistant enterococci in acute-care hospitals that employ strict infection control procedures. *Antimicrob Agents Chemother* 47:2492–2498. <https://doi.org/10.1128/AAC.47.8.2492-2498.2003>.
23. Mody L, Foxman B, Bradley S, McNamara S, Lansing B, Gibson K, Cassone M, Armbruster C, Mantey J, Min L. 2018. Longitudinal assessment of multidrug-resistant organisms in newly admitted nursing facility patients: implications for an evolving population. *Clin Infect Dis* 67:837–844. <https://doi.org/10.1093/cid/ciy194>.
24. Nucleo E, Caltagirone M, Marchetti VM, D'Angelo R, Fogato E, Confalonieri M, Reboli C, March A, Sleghele F, Soelva G, Pagani E, Aschbacher R, Miglia-vacca R, Pagani L. 2018. Colonization of long-term care facility residents in three Italian provinces by multidrug-resistant bacteria. *Antimicrob Resist Infect Control* 7:33. <https://doi.org/10.1186/s13756-018-0326-0>.
25. Bonilla HF, Zervos MA, Lyons MJ, Bradley SF, Hedderwick SA, Ramsey MA, Paul LK, Kauffman CA. 1997. Colonization with vancomycin-resistant *Enterococcus faecium*: comparison of a long-term-care unit with an acute-care hospital. *Infect Control Hosp Epidemiol* 18:333–339. <https://doi.org/10.2307/30141227>.
26. Heintz BH, Halilovic J, Christensen CL. 2010. Vancomycin-resistant enterococcal urinary tract infections. *Pharmacotherapy* 30:1136–1149. <https://doi.org/10.1592/phco.30.11.1136>.
27. Esposito S, Leone S, Noviello S, Lanniello F, Fiore M. 2007. Antibiotic resistance in long-term care facilities. *New Microbiol* 30:326–331.
28. McKinnell JA, Miller LG, Singh R, Kleinman K, Peterson EM, Evans KD, Dutciuc TD, Heim L, Gombosev A, Estevez M, Launer B, Tjoa T, Tam S, Bolaris MA, Huang SS. 2016. Prevalence of and factors associated with multidrug resistant organism (MDRO) colonization in 3 nursing homes. *Infect Control Hosp Epidemiol* 37:1485–1488. <https://doi.org/10.1017/ice.2016.215>.
29. McNeil SA, Malani PN, Chenoweth CE, Fontana RJ, Magee JC, Punch JD, Mackin ML, Kauffman CA. 2006. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. *Clin Infect Dis* 42:195–203. <https://doi.org/10.1086/498903>.
30. Stiefel U, Rao A, Pultz MJ, Jump RL, Aron DC, Donskey CJ. 2006. Suppression of gastric acid production by proton pump inhibitor treatment facilitates colonization of the large intestine by vancomycin-resistant *Enterococcus* spp. and *Klebsiella pneumoniae* in clindamycin-treated mice. *Antimicrob Agents Chemother* 50:3905–3907. <https://doi.org/10.1128/AAC.00522-06>.
31. Cetinkaya Y, Falk PS, Mayhall CG. 2002. Effect of gastrointestinal bleeding and oral medications on acquisition of vancomycin-resistant *Enterococcus faecium* in hospitalized patients. *Clin Infect Dis* 35:935–942. <https://doi.org/10.1086/342580>.
32. Harbarth S, Cosgrove S, Carmeli Y. 2002. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. *Antimicrob Agents Chemother* 46:1619–1628. <https://doi.org/10.1128/AAC.46.6.1619-1628.2002>.
33. O'Fallon E, Pop-Vicas A, D'Agata E. 2009. The emerging threat of multidrug-resistant gram-negative organisms in long-term care facilities. *J Gerontol A Biol Sci Med Sci* 64:138–141. <https://doi.org/10.1093/gerona/gln020>.
34. Ryan L, O'Mahony E, Wrenn C, FitzGerald S, Fox U, Boyle B, Schaffer K, Werner G, Klare I. 2015. Epidemiology and molecular typing of VRE bloodstream isolates in an Irish tertiary care hospital. *J Antimicrob Chemother* 70:2718–2724. <https://doi.org/10.1093/jac/dkv185>.
35. Oprea SF, Zaidi N, Donabedian SM, Balasubramaniam M, Hershberger E, Zervos MJ. 2004. Molecular and clinical epidemiology of vancomycin-resistant *Enterococcus faecalis*. *J Antimicrob Chemother* 53:626–630. <https://doi.org/10.1093/jac/dkh138>.
36. Elizaga ML, Weinstein RA, Hayden MK. 2002. Patients in long-term care facilities: a reservoir for vancomycin-resistant enterococci. *Clin Infect Dis* 34:441–446. <https://doi.org/10.1086/338461>.
37. Benenson S, Cohen MJ, Block C, Stern S, Weiss Y, Moses AE. 2009. Vancomycin-resistant enterococci in long-term care facilities. *Infect Control Hosp Epidemiol* 30:786–789. <https://doi.org/10.1086/598345>.
38. Brodrick HJ, Raven KE, Harrison EM, Blane B, Reuter S, Török ME, Parkhill J, Peacock SJ. 2016. Whole-genome sequencing reveals transmission of vancomycin-resistant *Enterococcus faecium* in a healthcare network. *Genome Med* 8:4. <https://doi.org/10.1186/s13073-015-0259-7>.
39. Stall N. 2012. Private rooms: a choice between infection and profit. *CMAJ* 184:24–25. <https://doi.org/10.1503/cmaj.109-4077>.
40. Silverblatt FJ, Tibert C, Mikolich D, Blazek-D'Arezzo J, Alves J, Tack M, Agatiello P. 2000. Preventing the spread of vancomycin-resistant enterococci in a long-term care facility. *J Am Geriatr Soc* 48:1211–1215. <https://doi.org/10.1111/j.1532-5415.2000.tb02592.x>.
41. Genao L, Buhr GT. 2012. Urinary tract infections in older adults residing in long-term care facilities. *Ann Longterm Care* 20:33–38.
42. Shah KJ, Cherabuddi K, Shultz J, Borgert S, Ramphal R, Klinker KP. 2018. Ampicillin for the treatment of complicated urinary tract infections caused by vancomycin-resistant *Enterococcus* spp (VRE): a single-center university hospital experience. *Int J Antimicrob Agents* 51:57–61. <https://doi.org/10.1016/j.ijantimicag.2017.06.008>.
43. Mody L, Saint S, Galecki A, Chen S, Krein SL. 2010. Knowledge of evidence-based urinary catheter care practice recommendations among healthcare workers in nursing homes. *J Am Geriatr Soc* 58:1532–1537. <https://doi.org/10.1111/j.1532-5415.2010.02964.x>.
44. Mody L, Meddings J, Edson BS, McNamara SE, Trautner BW, Stone ND, Krein SL, Saint S. 2015. Enhancing resident safety by preventing healthcare-associated infection: a national initiative to reduce catheter-associated urinary tract infections in nursing homes. *Clin Infect Dis* 61:86–94. <https://doi.org/10.1093/cid/civ236>.
45. Kaur J, Stone PW, Travers JL, Cohen CC, Herzig CTA. 2017. Influence of staff infection control training on infection-related quality measures in

- US nursing homes. *Am J Infect Control* 45:1035–1040. <https://doi.org/10.1016/j.ajic.2017.04.285>.
46. Willson M, Wilde M, Webb M-L, Thompson D, Parker D, Harwood J, Callan L, Gray M. 2009. Nursing interventions to reduce the risk of catheter-associated urinary tract infection: part 2. Staff education, monitoring and care techniques *J Wound Ostomy Continence Nurs* 36:137–154. <https://doi.org/10.1097/01.WON.0000347655.56851.04>.
47. D'Agata EM, Green WK, Schulman G, Li H, Tang Y-W, Schaffner W. 2001. Vancomycin-resistant enterococci among chronic hemodialysis patients: a prospective study of acquisition. *Clin Infect Dis* 32:23–29. <https://doi.org/10.1086/317549>.
48. Pop-Vicas A, Mitchell SL, Kandel R, Schreiber R, D'Agata E. 2008. Multidrug-resistant gram-negative bacteria in a long-term care facility: prevalence and risk factors. *J Am Geriatr Soc* 56:1276–1280. <https://doi.org/10.1111/j.1532-5415.2008.01787.x>.
49. Bell JM, Paton JC, Turnidge J. 1998. Emergence of vancomycin-resistant enterococci in Australia: phenotypic and genotypic characteristics of isolates. *J Clin Microbiol* 36:2187–2190.
50. Polk RE, Fox C, Mahoney A, Letcavage J, MacDougall C. 2007. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. *Clin Infect Dis* 44:664–670. <https://doi.org/10.1086/511640>.
51. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 40:373–383. [https://doi.org/10.1016/0021-9681\(87\)90171-8](https://doi.org/10.1016/0021-9681(87)90171-8).